V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Rocket Pharmaceuticals Executive Compensation (FY25)

RCKT · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Gaurav Shah
Latest say-on-pay support
=
May 20, 2026
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The Rocket Pharmaceuticals brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
Data as of October 22, 2026Latest filing (8-K): May 21, 2026
9 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Rocket Pharmaceuticals brief$1,500Get the executive brief
Velarion Member, one year
229 figures on this page: 224 cited to the filing that reported them, 5 calculated from figures it prints. See the citations
This company is not required to report a chief executive pay ratio.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Gaurav Shah: $6,841,407 → $3,510,241 (48.7% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Rocket Pharmaceuticals' chief executive and what were they paid?
Gaurav Shah, Chief Executive Officer and Director, received $3,510,241 in total compensation for fiscal 2025. Shah's total was 48.7% lower than the $6,841,407 reported for fiscal 2024.
What was Rocket Pharmaceuticals' say-on-pay result?
For fiscal 2025, the say-on-pay proposal drew 97.3% support at the meeting held May 20, 2026.
Which companies are in Rocket Pharmaceuticals' peer group?
The disclosed peer group names Agios Pharmaceuticals, Inc., Allogene Therapeutics, Inc., Amicus Therapeutics, Inc., Beam Therapeutics Inc. and bluebird bio, Inc., among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Gaurav Shah
Chief Executive Officer
◇—◇◇◇—◇◇
Pharm.D. Kinnari Patel
President and Chief Operating Officer
◇—◇◇◇—◇◇
Mayo Pujols
Chief Technical Officer, Executive Vice President
◇◇◇◇◇—◇◇
Raj Prabhakar
Chief Business Officer, Senior Vice President
◇◇◇◇——◇◇
Jonathan Schwartz
Chief Medical and Gene Therapy Officer
◇—◇◇◇—◇◇
John Militello
Principal Accounting Officer and Interim Principal Financial Officer, Vice President
Served on an interim basis
◇—◇◇◇—◇◇
Carlos Garcia-Parada
Former Chief Financial Officer and Principal Financial Officer
Departed during or after this year
◇—◇◇——◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Gaurav Shah
Chief Executive Officer
◇—◇◇◇—◇◇
Pharm.D. Kinnari Patel
President, Head of R&D and Chief Operating Officer
◇—◇◇◇—◇◇
Mayo Pujols
Chief Technical Officer, Executive Vice President
◇◇◇◇◇—◇◇
Jonathan Schwartz
Chief Medical and Gene Therapy Officer
◇—◇◇◇—◇◇
John Militello
Principal Accounting Officer and Former Interim Principal Financial Officer, Vice President
Served on an interim basis
◇◇◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Gaurav Shah
Chief Executive Officer
◇—◇◇◇—◇◇
Pharm.D. Kinnari Patel
President, Head of R&D and Chief Operating Officer
◇—◇◇◇—◇◇
Aaron Ondrey
Chief Financial Officer, Principal Financial Officer
◇—◇◇◇—◇◇
Jonathan Schwartz
Chief Medical and Gene Therapy Officer
◇—◇◇◇—◇◇
Martin Wilson
General Counsel and Chief Corporate Officer, Senior Vice President, Interim Principal Financial Officer
Served on an interim basis
◇—◇◇◇—◇◇
John Militello
Principal Accounting Officer and Former Interim Principal Financial Officer, Vice President
Departed during or after this year
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Christopher Stevens
Chief Operating Officer
◇◇◇◇◇—◇◇
Gaurav Shah
Chief Executive Officer and Director
◇—◇◇◇—◇◇
Martin Wilson
General Counsel and Chief Corporate Officer, Senior Vice President, Interim Principal Financial Officer
Served on an interim basis
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Christopher StevensRSU——————◇
Christopher StevensOPTION——————◇
Gaurav D. ShahOPTION——————◇
Gaurav D. ShahRSU——————◇
Martin WilsonRSU——————◇
Martin WilsonOPTION——————◇
Fiscal 2022, 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Martin WilsonOption◇—◇—
RSU◇◇——
Option◇—◇—
Option◇—◇—
Christopher StevensRSU◇◇——
Option◇—◇—
Gaurav ShahOption◇—◇—
Option◇—◇—
Option◇—◇—
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Christopher Stevens
Chief Operating Officer · Terms as announced by the company · citing a 2026 filing
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Gaurav Shah
Chief Executive Officer and Director · Terms as announced by the company · citing a 2026 filing
Severance multiple◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Martin Wilson
General Counsel and Chief Corporate Officer, Senior Vice President, Interim Principal Financial Officer · Terms as announced by the company · citing a 2026 filing
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Piratip Pratumsuwan
◇◇◇———◇
Mikael Dolsten
◇◇———◇◇
Peter Fong
◇◇————◇
Carsten Boess
◇◇————◇
Pedro Granadillo
—◇————◇
Gotham Makker
—◇————◇
David Southwell
◇◇————◇
Roderick Wong
—◇————◇
Fady Malik
◇◇————◇
Elisabeth Björk
◇◇————◇
R. Keith Woods
◇—————◇
Gaurav Shah and Naveen Yalamanchi served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2024
  • Agios Pharmaceuticals, Inc. AGIO
  • Allogene Therapeutics, Inc. ALLO
  • Amicus Therapeutics, Inc. FOLD
  • Beam Therapeutics Inc. BEAM
  • bluebird bio, Inc. BLUE
  • BridgeBio Pharma, Inc. BBIO
  • CRISPR Therapeutics AG CRSP
  • Editas Medicine, Inc. EDIT
  • Intellia Therapeutics, Inc. NTLA
  • Krystal Biotech, Inc. KRYS
  • Mirati Therapeutics, Inc. MRTX
  • Regenxbio Inc. RGNX
  • Replimune Group, Inc. REPL
  • Rhythm Pharmaceuticals, Inc. RYTM
  • Tenaya Therapeutics, Inc. TNYA
  • Ultragenyx Pharmaceutical Inc. RARE
  • uniQure N.V. QURE

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 20, 2026=◇◇◇
2024June 18, 2025=◇◇◇
2023June 13, 2024=◇◇◇
2022June 22, 2023=◇◇◇
2020June 14, 2021=◇◇◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Gaurav Shah (Chief Executive Officer and Director), FY2025 total compensation $3,510,241 (base salary $671,076) [exec_comp, SEC accession 0001140361-26-013335, filed 2026-04-06]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Rocket Pharmaceuticals files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Rocket Pharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Rocket Pharmaceuticals sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Rocket Pharmaceuticals' disclosed peer group is defensible, who names Rocket Pharmaceuticals back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
229 figures on this page: 224 cited to the filing that reported them, 5 calculated from figures it prints.
224 cited to the filing
5 calculated from the filing

Documents cited

  1. 0001140361-26-022311
  2. 0001140361-26-013335
    2025 Director Compensation Table · 2025 Outstanding Equity Awards at Fiscal Year-End · 2025 Summary Compensation Table · Compensation Discussion and Analysis · and 2 more sections
  3. 0001140361-25-022996
  4. 0001140361-25-016656
    2024 Summary Compensation Table
  5. 0001140361-24-030718
  6. 0001140361-24-023041
    2023 Summary Compensation Table
  7. 0001140361-23-031184
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001140361-23-021702
    2022 Summary Compensation Table
  9. 0001140361-21-021716
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Rocket Pharmaceuticals executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/RCKT (accessed 2026).
Short form: data: Velarion

The Rocket Pharmaceuticals brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
9 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Rocket Pharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Rocket Pharmaceuticals discloses

The companies named in RCKT's own disclosed peer group.

Agios Pharmaceuticals, Inc.Allogene Therapeutics, Inc.Amicus Therapeutics, Inc.Beam Therapeutics Inc.bluebird bio, Inc.BridgeBio Pharma, Inc.CRISPR Therapeutics AGEditas Medicine, Inc.Intellia Therapeutics, Inc.Krystal Biotech, Inc.Mirati Therapeutics, Inc.Regenxbio Inc.Replimune Group, Inc.Rhythm Pharmaceuticals, Inc.Tenaya Therapeutics, Inc.Ultragenyx Pharmaceutical Inc.uniQure N.V.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy